QGEN Price Prediction Next Week
Technical Analysis Based on recent price action and technical indicators, QGEN shows bearish momentum with RSI at 25.04, indicating oversold conditions. The MACD reading of -1.22 confirms the downward trend. The stock is trading below both its 20-day (45.39) and 60-day (45.29) moving averages.
News Impact Recent earnings release shows mixed results. Q4 EPS of $0.61 missed consensus by $0.01, while revenue of $521.2M slightly beat estimates. The company's 2025 EPS guidance of at least $2.28 falls below consensus of $2.35, which has contributed to negative sentiment.
Analyst Consensus Multiple analyst updates paint a mixed picture:
- J.P. Morgan maintains Buy rating with $50 PT
- TD Cowen holds Hold rating with $49 PT
- UBS maintains Neutral, lowering PT to $48 The consensus price target stands at $50.82, suggesting potential upside.
Price Prediction (Next Week) Based on Fibonacci levels and current technical setup:
- Support levels: $40.51 (S1), $38.67 (S2)
- Resistance levels: $46.48 (R1), $48.32 (R2)
- Pivot point: $43.50
Expected price range: $41.00 - $43.50
Recommendation: SELL Given the bearish technical indicators, missed earnings, and lower guidance, QGEN is likely to test lower support levels next week. Traders should consider selling positions with a target of $41.00 and stop loss at $44.50.
QGEN Similar Chart Price Prediction
The price of QGEN is predicted to go up -10.19%, based on the high correlation periods with LILA. The similarity of these two price pattern on the periods is 96.52%.
QGEN
LILA
Down: -10.19%Similarity: 96.52%
QGEN Revenue Forecast
QGEN EPS Forecast
QGEN FAQs
What is bull’s view on QGEN?
What is bear's view on QGEN?
What is QGEN revenue forecast for next quarter？
What is QGEN eps forecast for next quarter？
QGEN VS S&P500
Qiagen's long-term growth prospects in the life science and diagnostic markets will not dissolve just because the pandemic turns into an endemic situation.
Qiagen aims to expand its infectious disease platform with a variety of new instrument and test menu introductions, which should support strong growth in the long run.
With its QuantiFERON technology, Qiagen aims to grow in large market opportunities like TB and lyme disease.
QGEN Analyst's Forecast
Shubhangi Gupta
HSBC
Strong Buy → Hold
2024-10-17
Price Target
n/a
Downside
0%
HSBC analyst Shubhangi Gupt downgraded Qiagen to Hold from Buy with a $49 price target.
